Speakers

Expand/Collapse

Alexandre Di Paolo
Senior Business Development Manager
TriLink BioTechnologies

Day Two

Thursday 27th January 2021

10:45 am | mRNA Modifications that Matter: Modified Uridine as a Therapeutic Tool

10:45 am | mRNA Modifications that Matter: Modified Uridine as a Therapeutic Tool

Alexandre Di Paolo
Senior Business Development Manager
TriLink BioTechnologies

Allison August
VP, Clinical Development, Infectious Diseases
Moderna

Day One

Wednesday 26th January 2021

2:15 pm | Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial

5:00 pm | Panel Discussion

2:15 pm | Lipid-Encapsulated mRNA Delivery of a Monoclonal Antibody with Neutralizing Activity Against Chikungunya Virus: Results From a Phase 1 Trial

5:00 pm | Panel Discussion

Allison August
VP, Clinical Development, Infectious Diseases
Moderna

Amar Deep Sharma
Group Leader
Hannover Medical School

Day One

Wednesday 26th January 2021

12:45 pm | Discovering Novel Methods to Promote Protein Replacement in Chronic End-Stage Disease

12:45 pm | Discovering Novel Methods to Promote Protein Replacement in Chronic End-Stage Disease

Amar Deep Sharma
Group Leader
Hannover Medical School

Andreas Kuhn
Senior VP - RNA Biochemistry & Manufacturing
BioNTech

Day One

Wednesday 26th January 2021

8:15 am | Chair’s Opening Remarks

8:15 am | Chair’s Opening Remarks

Andreas Kuhn
Senior VP - RNA Biochemistry & Manufacturing
BioNTech

Arun Kumar
Preclinical Vaccines Development Lead
Coalition for Epidemic Preparedness Innovations (CEPI)

Day One

Wednesday 26th January 2021

8:30 am | Landscaping mRNA- Based Vaccine Technologies for the Future

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

8:30 am | Landscaping mRNA- Based Vaccine Technologies for the Future

Arun Kumar
Preclinical Vaccines Development Lead
Coalition for Epidemic Preparedness Innovations (CEPI)

Carsten Rudolph
CEO
Ethris

Day Two

Thursday 27th January 2021

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

Carsten Rudolph
CEO
Ethris

Christian Hotz
Director - In Situ Therapy
BioNTech

Day One

Wednesday 26th January 2021

11:15 am | Local Immunotherapy with Cytokine-Encoding mRNAs for Immuno-Oncology

11:15 am | Local Immunotherapy with Cytokine-Encoding mRNAs for Immuno-Oncology

Christian Hotz
Director - In Situ Therapy
BioNTech

Danilo Casimiro
CSO
Sanofi Pasteur

Day One

Wednesday 26th January 2021

5:00 pm | Panel Discussion

6:15 pm | Chair’s Closing Remarks & End of Conference Day One

6:15 pm | Chair’s Closing Remarks & End of Conference Day One

5:00 pm | Panel Discussion

Danilo Casimiro
CSO
Sanofi Pasteur

Dariush Mohammadyani
Senior Scientist
Johnson & Johnson

Day Two

Thursday 27th January 2021

5:30 pm | Computational Approaches to Develop Next-Generation mRNA- Based Therapeutic Delivery Methods

5:30 pm | Computational Approaches to Develop Next-Generation mRNA- Based Therapeutic Delivery Methods

Dariush Mohammadyani
Senior Scientist
Johnson & Johnson

Darwin Asa
Market Development Manager
ThermoFisher Scientific

Day Two

Thursday 27th January 2021

3:30 pm | Plan Now or Fail Later: Why Raw Materials Matter

3:30 pm | Plan Now or Fail Later: Why Raw Materials Matter

Darwin Asa
Market Development Manager
ThermoFisher Scientific

David M. Brown
Associate Director
RNAimmune

Day One

Wednesday 26th January 2021

5:30 pm | Engineering and Results of Next-Generation COVID-19 Vaccines - Sponsored by Codex DNA

5:30 pm | Engineering and Results of Next-Generation COVID-19 Vaccines - Sponsored by Codex DNA

David M. Brown
Associate Director
RNAimmune

Drew Weissman
Professor - Vaccine Research
University of Pennsylvania, Perelman School of Medicine

Day Two

Thursday 27th January 2021

12:15 pm | Tissue Specific Targeting of mRNA to Increase Therapeutic & Vaccine Efficacy

12:15 pm | Tissue Specific Targeting of mRNA to Increase Therapeutic & Vaccine Efficacy

Drew Weissman
Professor - Vaccine Research
University of Pennsylvania, Perelman School of Medicine

Dushyant Varshney
Executive VP & CTO
Arcturus Therapeutics

Day One

Wednesday 26th January 2021

4:30 pm | Rapid Commercialization & Technology Transfer of mRNA Vaccines & Therapeutics

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

4:30 pm | Rapid Commercialization & Technology Transfer of mRNA Vaccines & Therapeutics

Dushyant Varshney
Executive VP & CTO
Arcturus Therapeutics

Elaine Peters
Director - Analytical Lead
Genentech

Elaine Peters
Director - Analytical Lead
Genentech

Heinrich Haas
VP – Formulation & Delivery
BioNTech

Day Two

Thursday 27th January 2021

9:15 am | Approaches Towards Next Generation mRNA Delivery Systems

9:15 am | Approaches Towards Next Generation mRNA Delivery Systems

Heinrich Haas
VP – Formulation & Delivery
BioNTech

Henrik Ihre
Global Director Strategic Technologies
Cytiva

Day One

Wednesday 26th January 2021

12:15 pm | Manufacturing Considerations of mRNA- Based Therapeutics

12:15 pm | Manufacturing Considerations of mRNA- Based Therapeutics

Henrik Ihre
Global Director Strategic Technologies
Cytiva

Jacob Becraft
Co-Founder & CEO
Strand Therapeutics

Day Two

Thursday 27th January 2021

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

Jacob Becraft
Co-Founder & CEO
Strand Therapeutics

Jaspreet Khurana
Director - Platform & Discovery
Strand Therapeutics

Day Two

Thursday 27th January 2021

1:30 pm | Programming mRNA to Enable Cell-Type Specific Target Expression

1:30 pm | Programming mRNA to Enable Cell-Type Specific Target Expression

Jaspreet Khurana
Director - Platform & Discovery
Strand Therapeutics

Julian Mochayedi
Strategic Marketing Manager – mRNA solutions
Merck KGaA

Day Two

Thursday 27th January 2021

9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design

9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design

Julian Mochayedi
Strategic Marketing Manager – mRNA solutions
Merck KGaA

Lloyd Jeffs
Senior Director of Pharmaceutical Development
Precision NanoSystems

Day One

Wednesday 26th January 2021

2:45 pm | Accelerated Development of Self-Amplifying mRNA (saRNA) Vaccines

2:45 pm | Accelerated Development of Self-Amplifying mRNA (saRNA) Vaccines

Lloyd Jeffs
Senior Director of Pharmaceutical Development
Precision NanoSystems

Lucia Lapazio
Group Lead - mRNA
Sanofi

Day One

Wednesday 26th January 2021

9:30 am | Advancing Strategies & CMC for mRNA- Based Therapeutic Development

9:30 am | Advancing Strategies & CMC for mRNA- Based Therapeutic Development

Lucia Lapazio
Group Lead - mRNA
Sanofi

Marcus Wilhelmsson
Professor Chalmers
University of Technology

Day Two

Thursday 27th January 2021

12:45 pm | Monitoring Functional Cellular Uptake of mRNA Using Native-Like Fluorophores & Challenges with Expanding the Methodology to In Vivo

12:45 pm | Monitoring Functional Cellular Uptake of mRNA Using Native-Like Fluorophores & Challenges with Expanding the Methodology to In Vivo

Marcus Wilhelmsson
Professor Chalmers
University of Technology

Maria-Teresa Peracchia
Global Head Drug Delivery and Product Integration
Sanofi

Day Two

Thursday 27th January 2021

6:00 pm | Chair’s Closing Remarks & End of mRNA- Based Therapeutics Summit Europe

9:00 am | Chair’s Opening Remarks

6:00 pm | Chair’s Closing Remarks & End of mRNA- Based Therapeutics Summit Europe

9:00 am | Chair’s Opening Remarks

Maria-Teresa Peracchia
Global Head Drug Delivery and Product Integration
Sanofi

Mathieu Ghadanfar
CMO
Ziphius Vaccines

Day One

Wednesday 26th January 2021

3:15 pm | Reconceptualizing Vaccine Approaches Across the Development Pipeline

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

3:15 pm | Reconceptualizing Vaccine Approaches Across the Development Pipeline

Mathieu Ghadanfar
CMO
Ziphius Vaccines

Michael Wourms
SVP, Head of mRNA Business Unit
Arranta Bio

Day Two

Thursday 27th January 2021

1:15 pm | Integrating a Fragmented mRNA- Based Therapies Supply Chain

1:15 pm | Integrating a Fragmented mRNA- Based Therapies Supply Chain

Michael Wourms
SVP, Head of mRNA Business Unit
Arranta Bio

Michiel Lodder
CEO
20Med Therapeutics

Day Two

Thursday 27th January 2021

10:15 am | Harnessing an Alternative Non-Viral Polymer- Based Drug Delivery System for mRNA- Based Therapeutics

10:15 am | Harnessing an Alternative Non-Viral Polymer- Based Drug Delivery System for mRNA- Based Therapeutics

Michiel Lodder
CEO
20Med Therapeutics

Nargisse El Hajjami
Senior Consultant - Novel Modalities BioProcessing Strategy Operationalization
Merck KGaA

Day Two

Thursday 27th January 2021

9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design

9:45 am | Keys to Successful mRNA Manufacturing from Development, Purification and Lipid Formulation to Facility Design

Nargisse El Hajjami
Senior Consultant - Novel Modalities BioProcessing Strategy Operationalization
Merck KGaA

Patrick Finn
Senior Director - Rare Diseases
Moderna

Day Two

Thursday 27th January 2021

3:00 pm | Strategies of mRNA- Based Therapeutics to Replace Enzymes for Rare Diseases

3:00 pm | Strategies of mRNA- Based Therapeutics to Replace Enzymes for Rare Diseases

Patrick Finn
Senior Director - Rare Diseases
Moderna

Rok Sekirnik
Head Process Development for mRNA and pDNA
BIA Separations

Day One

Wednesday 26th January 2021

9:00 am | mRNA: Removing Bottlenecks in Process Development & Manufacturing

9:00 am | mRNA: Removing Bottlenecks in Process Development & Manufacturing

Rok Sekirnik
Head Process Development for mRNA and pDNA
BIA Separations

Roland Pach
Global Expert Cell & Gene Therapy Analytics
Roche Pharmaceuticals

Roland Pach
Global Expert Cell & Gene Therapy Analytics
Roche Pharmaceuticals

Sophia Shamsi
Research Analyst
Beacon Targeted Therapies

Day One

Wednesday 26th January 2021

3:45 pm | The mRNA Landscape & Beyond

3:45 pm | The mRNA Landscape & Beyond

Sophia Shamsi
Research Analyst
Beacon Targeted Therapies

Thomas Langenickel
CMO
Ethris

Day One

Wednesday 26th January 2021

11:45 am | Targeting Immunomodulation with mRNA- Based Therapeutics

11:45 am | Targeting Immunomodulation with mRNA- Based Therapeutics

Thomas Langenickel
CMO
Ethris

Tom Barnes
CEO
Orna Therapeutics

Day One

Wednesday 26th January 2021

5:45 pm | The Therapeutic Potential of oRNA

5:45 pm | The Therapeutic Potential of oRNA

Day Two

Thursday 27th January 2021

5:00 pm | Panel Discussion

5:00 pm | Panel Discussion

Tom Barnes
CEO
Orna Therapeutics

Vittorio Sebastiano
Co-founder & Scientific Advisory Board Chairman
Turn Biotechnologies

Day Two

Thursday 27th January 2021

5:00 pm | Panel Discussion

4:00 pm | Epigenetic Reprogramming of Aging (ERA): mRNA- Based Solution for Age-Related Diseases

4:00 pm | Epigenetic Reprogramming of Aging (ERA): mRNA- Based Solution for Age-Related Diseases

5:00 pm | Panel Discussion

Vittorio Sebastiano
Co-founder & Scientific Advisory Board Chairman
Turn Biotechnologies

Volker Germaschewski
Senior VP - Research & Development
eTheRNA Immunotherapies NV

Day One

Wednesday 26th January 2021

10:00 am | Engineering the Future of mRNA Therapies

10:00 am | Engineering the Future of mRNA Therapies

Volker Germaschewski
Senior VP - Research & Development
eTheRNA Immunotherapies NV